Treatment of chronic lymphocytic leukemia and lymphosarcoma with a new chlorambucil ester of prednisolone (Leo 1031) (NSC‐134087) | Zendy

Aungst C. William | Zendy; Mittelman Arnold | Zendy; Murphy Gerald P. | Zendy

Premium

Treatment of chronic lymphocytic leukemia and lymphosarcoma with a new chlorambucil ester of prednisolone (Leo 1031) (NSC‐134087)

Author(s) -

Aungst C. William,

Mittelman Arnold,

Murphy Gerald P.

Publication year - 1975

Publication title -

journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.201

H-Index - 111

eISSN - 1096-9098

pISSN - 0022-4790

DOI - 10.1002/jso.2930070604

Subject(s) - chlorambucil , medicine , chronic lymphocytic leukemia , prednisolone , chemotherapy , complete remission , leukemia , fludarabine , gastroenterology , oncology , cyclophosphamide

A new chlorambucil ester of prednisolone (LEO 1031) has been evaluated in patients with advanced lymphocytic lymphosarcoma and chronic lymphocytic leukemia. All 11 patients had been previously treated with radiotherapy and/or combination chemotherapy. Three complete remissions and one partial remission were seen in 4/7 lymphocytic lymphosarcoma patients treated with LEO 1031. In the chronic lymphocytic leukemia group, 3/4 have had benefit. This new drug is considered worthy of further trial.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research